Back to top
more

Reata Pharmaceuticals, Inc. (RETA)

(Delayed Data from NSDQ)

$80.41 USD

80.41
117,440

+2.31 (2.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $80.37 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -833.33% and 13.86%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 18.52% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Entrada Therapeutics, Inc. (TRDA) delivered earnings and revenue surprises of -81.40% and 7.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7%

by Zacks Equity Research

Reata's (RETA) prior approval supplement application to update the drug substance specification for Skyclarys gets FDA's nod. Shares of the company gain 7% on Wednesday in response.

Reata Pharmaceuticals, Inc. (RETA) Moves 7.0% Higher: Will This Strength Last?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS

by Zacks Equity Research

Reata (RETA) gets FDA acceptance for the filing of new drug application supplement approval for Skyclarys' release.

Why Is Reata Pharmaceuticals, Inc. (RETA) Up 6.9% Since Last Earnings Report?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PTC Therapeutics' (PTCT) Rare Disease Drug Fails in Study

by Zacks Equity Research

PTC Therapeutics' (PTCT) vatiquinone did not achieve its primary endpoint in a late-stage study in treating Friedreich Ataxia patients. Shares decline 21% post the news.

Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

by Zacks Equity Research

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.

Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 80.53% and 252.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -30.86% and 64.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Janux Therapeutics, Inc. (JANX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Janux Therapeutics, Inc. (JANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are likely to have driven first-quarter sales.

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Therapeutics' (ASRT) Q1 earnings call, investors will likely focus on the sales performance of its rheumatology, pain and inflammation medicines.

Here's Why You Should Invest in Larimar (LRMR) Stock Now

by Zacks Equity Research

Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.

Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Telesis Bio (TBIO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Reata (RETA) Stock Doubles This Year on Skyclarys FDA Nod

by Zacks Equity Research

Reata Pharmaceuticals (RETA) stock more than doubles this year, owing to approval for its rare disease drug.

US Government Assures Fund Accessibility to SVB (SIVB) Clients

by Zacks Equity Research

Following the collapse of Silicon Valley Bank (SIVB), the go-to bank for US tech startups, U.S. banking regulators step in to assure access to funds to the bank's customers, especially startups.

Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug

by Zacks Equity Research

Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -1,800% and 80.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio, Inc. (PRVB) Surges 11.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Provention Bio, Inc. (PRVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.